Phreesia, Inc.
NYSE:PHRMedical - Healthcare Information Services
+$0.08 today
- Market cap
- $760.99M
- Beta
- 0.88
- P/E (TTM)
- 62.6
- EPS (TTM)
- $0.15
Volume 0.86M
Average 1.97M
PHR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Phreesia, Inc.NYSE: PHR
Capital Expenditures · Q1 FY2027 · quarter ended Apr 2026
Capital expenditures declines year over year
Q1 FY2027 capital expenditures of $4.31M (cash outflow) fell 41.7% year over year, ahead of the -47.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 68.4% from the prior quarter. Over 3 fiscal years it compounded at -24.9% a year.
Context
- Capital expenditures amounted to 2.3% of revenue in FY2026, down 3.4 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2026 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -41.7% holds above the trailing-twelve-month pace of -47.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2026
- (11.1M) USD
- Year-over-year change
- +53.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | (11.1M) | +53.9% |
| FY2025 | 2025-01-31 | (24.09M) | +4.0% |
| FY2024 | 2024-01-31 | (25.1M) | +4.2% |
| FY2023 | 2023-01-31 | (26.2M) | +14.9% |
| FY2022 | 2022-01-31 | (30.81M) | — |
Capital Expenditures vs competitors
How PHR compares with its peers on the latest reported figures
- PHR's LTM Apr 2026 capital expenditures of $11.91M is the 8th largest of the 11 companies compared; the peer median is $27.23M.
- Its year-over-year change of -47.0% is the 7th highest of 11, against a peer median of -18.8%.
- Capital expenditures amounts to 2.4% of revenue for PHR, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $44.11M | -6.4% | -12.7% | 3.6% | |
| LTM Mar 2026 | $38.69M | -31.1% | -60.0% | 4.9% | |
| LTM Mar 2026 | $36.87M | -60.9% | -18.6% | 1.5% | |
| LTM Aug 2026 | $35.5M | -60.6% | -7.9% | 4.0% | |
| LTM Jan 2026 | $33.27M | +68.5% | — | 39.7% | |
| LTM Mar 2026 | $21.19M | -49.2% | +7.7% | 3.1% | |
| LTM Mar 2026 | $19.69M | +488.5% | -3.0% | 19.7% | |
| LTM Apr 2026 | $11.91M | -47.0% | -24.9% | 2.4% | |
| LTM Sep 2026 | $8.27M | +35.5% | -41.9% | 3.1% | |
| LTM Sep 2026 | $4.2M | +84.7% | -43.5% | 1.6% | |
| LTM Mar 2026 | $1.09M | -74.9% | -21.4% | 0.4% | |
| Peer median (excluding PHR) | $27.23M | -18.8% | -18.6% | 3.4% | |
Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | (118.16M) | (176.15M) | (136.89M) | (58.53M) | 2.31M |
| Depreciation & Amortization | 21.3M | 25.3M | 29.49M | 27.89M | 31.45M |
| Deferred Income Tax | 143K | 434K | 228K | 214K | (13.27M) |
| Stock-Based Compensation | 36.14M | 58.78M | 71.7M | 66.98M | 67.45M |
| Change in Working Capital | (18.57M) | (3.86M) | (1.64M) | (6.49M) | (14.09M) |
| Accounts Receivables | (10.22M) | (11.13M) | (11.21M) | (8.81M) | (10.15M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.88M | 4.77M | (1.99M) | (3.23M) | 5.26M |
| Other Working Capital | (11.24M) | 2.5M | 11.56M | 5.55M | (9.2M) |
| Other Non-Cash Items | 4.43M | 5.37M | 4.73M | 2.33M | 4.96M |
| Operating Cash Flow | (74.71M) | (90.12M) | (32.38M) | 32.38M | 78.81M |
| Capital Expenditures | (30.81M) | (26.2M) | (25.1M) | (24.09M) | (11.1M) |
| Acquisitions (Net) | (34.42M) | 0 | (14.57M) | 0 | (153.19M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 15.71M |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (12.39M) | (21.47M) | (19.29M) | (15.38M) | (13.3M) |
| Investing Cash Flow | (65.23M) | (26.2M) | (39.67M) | (24.09M) | (161.88M) |
| Debt Repayment | (4.27M) | (5.95M) | (6.78M) | (7.81M) | 83.18M |
| Common Stock Issued | 245.81M | 4.92M | 0 | 3.93M | 3.83M |
| Common Stock Repurchased | (9M) | (19.38M) | (12.18M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.42M | (397K) | 1.84M | (7.61M) | (14.15M) |
| Financing Cash Flow | 234.97M | (20.8M) | (17.12M) | (11.49M) | 72.85M |
| Effect of Forex Changes | 0 | 0 | 0 | (106K) | (176K) |
| Net Change in Cash | 95.03M | (137.13M) | (89.16M) | (3.3M) | (10.39M) |
| Free Cash Flow | (105.52M) | (116.33M) | (57.48M) | 8.29M | 67.71M |
Phreesia, Inc.
NYSE:PHR
Intrinsic Alpha fair value
Locked
Current Price
$12.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.